In the mad scramble to find safe and effective drugs to treat patients suffering from COVID-19, the winners and losers amongst the litany of candidates are starting to emerge, with a previously-strong contender—hydroxychloroquine—falling from favor with the FDA, and another commonly-used drug seeing success in a major clinical trial. The
In the race to provide effective treatments for patients stricken with COVID-19, hydroxychloroquine—an already available, albeit now controversial, drug—is considered to be amongst the front-running candidates in the fight against the coronavirus that’s behind the pandemic. But despite promising in vitro study results (and a premature endorsement by President Donald
The US Food and Drug Administration has granted a group of researchers approval to proceed with the use of the controversial drug psilocybin, a psychedelic compound naturally produced in about 200 species of mushrooms, to treat patients suffering from treatment-resistant depression. This comes as welcome news for researchers that study psychedelic drugs, as current drug laws inhibit the study into the potential medical effects that the forbidden fungus may have to offer.
Not Target, not Walgreen, and not even GNC – according to the New York Attorney General’s office, which just issued a ‘cease and desist’ letter to all four major purveyors of nutritional supplements. According to a story in yesterday’s NY Times on-line health blog, tests showed that four out of five of the companies’ popular products did not contain the key ingredients listed on their labels. What they did contain was plenty of fillers – some of which were unlisted and could be harmful to consumers’ health.